REGULATORY

Nasal Steroid Used as “Reference Drug” for Xolair in Special Re-Pricing

January 23, 2020

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

The application of a new special rule for “indication re-pricing” to Novartis’ anti-IgE antibody Xolair (omalizumab), which was approved for the treatment of pollen allergy in December, was decided by referring to a nasal steroid that carries an allergic rhinitis…

To read the full story

Xolair Faces 37.3% Price Slash, Keytruda 20.9% in April: MHLW
March 5, 2020
Xolair’s Re-Pricing Decided, but Regulators and Novartis Were at Odds over Patient Projections
March 2, 2020
Japan’s Special Re-Pricing Rules to Hit 17 Drugs in April; Potentially Big Slash for Keytruda, Lixiana
January 22, 2020

REGULATORY

ONODERA GT’s Parkinson’s Gene Therapy Gets Sakigake Tag
June 10, 2026
Cabinet Approves Immunization Act Revision to Cover Antibody Drugs
June 10, 2026
LDP Lawmakers Seek Routine HPV Vaccinations for Males by April 2027
June 10, 2026
MHLW Lifts Part of Approval Conditions for Takeda’s Vyvanse
June 9, 2026
Drug Makers Seek Govt Support for Immunoglobulin Plant Investments: LDP Hearing
June 9, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Are Technical Discussions Enough for Japan’s CEA System?

By Ken Yoshino

Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…

COLUMN

The Patient North Star: How Gilead Japan Redefined Innovation

By Philip Carrigan

In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…